Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Schema for the phase II Randomized Observation versus

Published bySusanto Darmali Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Schema for the phase II Randomized Observation versus"— Presentation transcript:

1 Figure 2 Schema for the phase II Randomized Observation versus
Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) trial Figure 2 | Schema for the phase II Randomized Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) trial. Men with metachronous hormone-naive oligometastatic disease will be enrolled and dynamically randomized to the schema as shown. AP, alkaline phosphatase; CTCs, circulating tumour cells; ctDNA, cell-free circulating tumour DNA; LDH, lactate dehydrogenase; PBMC, peripheral blood mononuclear cells; SABR, stereotactic ablative radiation; SBRT, stereotactic radiation therapy; T, serum testosterone. ORIOLE is sponsored by the National Cancer Institute (NCI) 1U01CA and a Movember-PCF Challenge Award. Tosoian, J. J. et al. (2016) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Nat. Rev. Urol. doi: /nrurol

Download ppt "Figure 2 Schema for the phase II Randomized Observation versus"

Similar presentations

Prostate Cancer Cancer: Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer.

Prostate Cancer Cancer: Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer.
Breast SSG: SABR and Oligometastatic Disease

Breast SSG: SABR and Oligometastatic Disease
Compassionate People World Class Care

Compassionate People World Class Care
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study

Figure 2 Recruitment of experts to the Delphi study
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Risk-adapted and response-adapted

Figure 3 Risk-adapted and response-adapted
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 3 Semantic model of the active surveillance (AS) timeline

Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Similar presentations

Ads by Google